Sign in

Trial result ·

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study looked at kids with immune thrombocytopenia, or ITP. Their ITP had lasted a long time. In the main trial, kids got avatrombopag or a dummy drug. Chance decided which kid got which. This report took a fresh look at the first 12 weeks. The team checked if traits at the start changed how kids did. They also looked at planned pauses in the dose.

What they found

A rise meant 2 counts in a row of at least 50. On the dummy drug, no kid had this rise by day 15 or 22. Kids on avatrombopag had this rise more often by those days. This changed only a little between groups with different traits at the start. Of 54 kids on avatrombopag, 50 reached a count of at least 30. The dose was often paused when counts went above 250. In some kids, the good count did not last. Most of them had a dose pause at counts of 250 to 400.

What it means for patients

The authors say avatrombopag gave a useful platelet rise in kids with ITP. This held across groups with different traits and backgrounds. These kids had tried many past drugs that had not worked well. The authors say the dose pauses may have affected the results. In daily care, counts of 250 to 400 would not pause the drug.

Why it is not certain yet

This look at the data was not planned at the start. Such later checks can show links but cannot prove them. It only covered the first 12 weeks. The dose pauses in the trial may have changed the results. The abstract does not give the number of kids on the dummy drug. It also does not report on side effects.

Source

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial.

PubMed · PMID 42481135

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Immune thrombocytopenia (ITP) publications